Literature DB >> 9242456

Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.

J M Varley1, G McGown, M Thorncroft, M F Santibanez-Koref, A M Kelsey, K J Tricker, D G Evans, J M Birch.   

Abstract

We have previously reported on the analysis of TP53 coding mutations in 12 classic Li-Fraumeni syndrome (LFS) families plus 9 families that were Li-Fraumeni-like (LFL) families (J. M. Birch et al., Cancer Res., 54: 1298-1304, 1994). Mutations were found in 6 of 12 LFS families and in 1 of 9 LFL families. We have now extended these studies to include an additional nine LFS and nine LFL families, and TP53 mutations have been detected in eight of nine LFS families and in three of nine LFL families. Six of the new mutations described here are the same as those previously identified in other Li-Fraumeni families and are missense mutations at codons 245, 248, and 273 (in two families); a nonsense mutation at codon 209; and a mutation at the splice donor site in exon 4. The other five mutations are novel germ-line mutations and include missense mutations at codons 136 and 344, a 2-bp deletion within codon 191, a splice acceptor mutation in intron 3, and a 167-bp deletion of part of exon 1 and intron 1. In addition, we have detected a codon 175 mutation in a family previously reported as TP53 negative. To summarize all of the data from the families we have studied in this and our previous report (J. M. Birch et al., Cancer Res., 54: 1298-1304, 1994), mutations have been detected in 15 of 21 LFS families (71%) and in 4 of 18 LFL families (22%). These figures are somewhat higher than those previously reported by us and others for the frequency of TP53 mutations in LFS and LFL families. This could reflect our analysis of all 11 exons of TP53, including noncoding regions, as well as the use of direct sequencing rather than other less-sensitive mutation detection methods.

Entities:  

Mesh:

Year:  1997        PMID: 9242456

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

Review 1.  Umbilical cord blood transplantation.

Authors:  A M Will
Journal:  Arch Dis Child       Date:  1999-01       Impact factor: 3.791

Review 2.  Genes and cancer.

Authors:  J M Birch
Journal:  Arch Dis Child       Date:  1999-01       Impact factor: 3.791

3.  Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.

Authors:  Judy Mouchawar; Christopher Korch; Tim Byers; Todd M Pitts; Efang Li; Margaret R E McCredie; Graham G Giles; John L Hopper; Melissa C Southey
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

4.  Pifithrin-Alpha Reduces Methamphetamine Neurotoxicity in Cultured Dopaminergic Neurons.

Authors:  Yun-Hsiang Chen; Eunkyung Bae; Hsi Chen; Seong-Jin Yu; Brandon K Harvey; Nigel H Greig; Yun Wang
Journal:  Neurotox Res       Date:  2019-05-08       Impact factor: 3.911

5.  Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients.

Authors:  Muhammad U Rashid; Sidra Gull; Kashif Asghar; Noor Muhammad; Asim Amin; Ute Hamann
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

6.  Lack of toxicity in a patient with germline TP53 mutation treated with radiotherapy.

Authors:  P Wong; K Han
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

Review 7.  [Soft tissue tumors in hereditary tumor syndromes].

Authors:  A Agaimy
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

8.  p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis.

Authors:  L Sivaraman; O M Conneely; D Medina; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

9.  Genetic screening for familial gastric cancer.

Authors:  Carla Oliveira; Gianpaolo Suriano; Paulo Ferreira; Paulo Canedo; Pardeep Kaurah; Rita Mateus; Ana Ferreira; António C Ferreira; Maria José Oliveira; Céu Figueiredo; Fátima Carneiro; Gisela Keller; David Huntsman; José Carlos Machado; Raquel Seruca
Journal:  Hered Cancer Clin Pract       Date:  2004-05-15       Impact factor: 2.857

10.  Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.

Authors:  D G R Evans; A Moran; R Hartley; J Dawson; B Bulman; F Knox; A Howell; F Lalloo
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.